Metastatic Gastric Cancer: Synergizing and Sequencing Targeted Therapy with First-Line Immunotherapy

References

• Janjigian YY, Shitara K, Moehler M et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, Phase III trial. The Lancet 398(10294), 27–40 (2021).
   PubMed Web of Science ®Google Scholar
• Xu J, Jiang H, Pan Y et al. ORIENT-16 Investigators . Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. JAMA 330(21), 2064 (2023).
   PubMed Web of Science ®Google Scholar
• Moehler MH, Kato K, Arkenau H-T et al. Rationale 305: Phase III study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). J. Clin. Oncol. 41(Suppl. 4), 286–286 (2023).
   Google Scholar
• Kang Y-K, Chen L-T, Ryu M-H et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, Phase III trial. Lancet Oncol. 23(2), 234–247 (2022).
   PubMed Web of Science ®Google Scholar
• Shitara K, Van Cutsem E, Bang Y-J et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 Phase III randomized clinical trial. JAMA Oncol. 6(10), 1571 (2020).
   PubMed Web of Science ®Google Scholar
• Rha SY, Oh D-Y, Yañez P et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, Phase III trial. Lancet Oncol. 24(11), 1181–1195 (2023).
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Kawazoe A, Bai Y et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the Phase III KEYNOTE-811 randomised placebo-controlled trial. Lancet 402(10418), 2197–2208 (2023).
   PubMed Web of Science ®Google Scholar
• Zhao JJ, Yap DWT, Chan YH et al. Low programmed death-ligand 1-expressing subgroup outcomes of first-line immune checkpoint inhibitors in gastric or esophageal adenocarcinoma. J. Clin. Oncol. 40(4), 392–402 (2022).
   PubMed Web of Science ®Google Scholar
• Yoon HH, Jin Z, Kour O et al. Association of PD-L1 expression and other variables with benefit from immune checkpoint inhibition in advanced gastroesophageal cancer: systematic review and meta-analysis of 17 Phase III randomized clinical trials. JAMA Oncol. 8(10), 1456 (2022).
   PubMed Web of Science ®Google Scholar
• Kundel Y, Sternschuss M, Moore A, Perl G, Brenner B, Goldvaser H. Efficacy of immune-checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: a systematic review and meta-analysis. Cancer Med. 9(20), 7613–7625 (2020).
   PubMed Web of Science ®Google Scholar
• Muro K, Chung HC, Shankaran V et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, Phase Ib trial. Lancet Oncol. 17(6), 717–726 (2016).
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Doi T, Jang RW et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase II Clinical KEYNOTE-059 trial. JAMA Oncol. 4(5), e180013 (2018).
   PubMed Web of Science ®Google Scholar
• Marabelle A, Le DT, Ascierto PA et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the Phase II KEYNOTE-158 study. J. Clin. Oncol. 38(1), 1–10 (2020).
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Özgüroğlu M, Bang Y-J et al. Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized Phase III KEYNOTE-061 trial. Gastric Cancer 25(1), 197–206 (2022).
   PubMed Web of Science ®Google Scholar
• Yu H-Y, Li C-P, Huang Y-H et al. Microsatellite instability, Epstein-Barr virus, and programmed cell death ligand 1 as predictive markers for immunotherapy in gastric cancer. Cancers 14(1), 218 (2022).
   PubMed Web of Science ®Google Scholar
• Bai Y, Xie T, Wang Z et al. Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer. J. Immunother. Cancer 10(3), e004080 (2022).
   PubMed Web of Science ®Google Scholar
• Naseem M, Barzi A, Brezden-Masley C et al. Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat. Rev. 66, 15–22 (2018).
   PubMed Web of Science ®Google Scholar
• Derks S, Liao X, Chiaravalli AM et al. Abundant PD-L1 expression in Epstein-Barr virus-infected gastric cancers. Oncotarget 7(22), 32925–32932 (2016).
   PubMed Web of Science ®Google Scholar
• Cao W, Xing H, Li Y et al. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. Biomark. Res. 10(1), 38 (2022).
   PubMed Web of Science ®Google Scholar
• Derks S, Van Laarhoven HWM. SPOTlight on GLOW. Cell Rep. Med. 4(10), 101233 (2023).
   PubMedGoogle Scholar
• Shah MA, Shitara K, Ajani JA et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, Phase III GLOW trial. Nat. Med. 29(8), 2133–2141 (2023).
   PubMed Web of Science ®Google Scholar
• Shitara K, Lordick F, Bang Y-J et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-Blind, Phase III trial. Lancet 401(10389), 1655–1668 (2023).
   PubMed Web of Science ®Google Scholar
• Wang C, Wang Y, Chen J et al. CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer. BMC Gastroenterol. 23(1), 283 (2023).
   PubMed Web of Science ®Google Scholar
• Kubota Y, Kawazoe A, Mishima S et al. Comprehensive clinical and molecular characterization of Claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. ESMO Open 8(1), 100762 (2023).
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Atlas Research Network . Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513(7517), 202–209 (2014).
   PubMed Web of Science ®Google Scholar
• Bang Y-J, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase III, open-label, randomised controlled trial. Lancet 376(9742), 687–697 (2010).
   PubMed Web of Science ®Google Scholar
• Triulzi T, Forte L, Regondi V et al. HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy. OncoImmunology 8(1), e1512942 (2019).
   PubMed Web of Science ®Google Scholar
• Tabernero J, Hoff PM, Shen L et al. Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB Phase III randomized clinical trial. Gastric Cancer 26(1), 123–131 (2023).
   PubMed Web of Science ®Google Scholar
• Hecht JR, Bang Y-J, Qin SK et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC-A randomized Phase III trial. J. Clin. Oncol. 34(5), 443–451 (2016).
   PubMed Web of Science ®Google Scholar